The EMA has validated the marketing application for PF-07307405, a Pfizer-Valneva Lyme disease vaccine candidate supported by Phase 3 data showing more than 70% efficacy.
Nina Bauer of FUJIFILM Cellular Dynamics shares hands-on experience manufacturing iPSCs, their increasing importance, and the technical bottlenecks standing in their way.
